Loading
BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity.
Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, somatic mutation 0.85). IntOGen calls it a driver in 4 cohorts (1 activating, 3 loss-of-function), covering Colon Adenocarcinoma, Colorectal Adenocarcinoma, Stomach Adenocarcinoma.
In plain words · BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.
BCL9 (B-cell CLL/lymphoma 9 protein) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 2 more.
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity.
No product in this corpus aims at BCL9 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
First described 1998. Earliest sequence paper UniProt cites for the protein: Willis T.G. et al, Blood, 1998, "Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21". Source.
Sources: HGNC HGNC:1008 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O00512 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000116128 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: colorectal cancer 0.57, gastric cancer 0.52, melanoma 0.51, skin cancer 0.54, breast cancer 0.53 (GraphQL API, CC0)); IntOGen BCL9 (driver in 4 cohorts (Act 1, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity. Location: Nucleus (UniProt). Locus 1q21.2 (HGNC).
Query for this target: (TITLE:"BCL9" OR ABSTRACT:"BCL9" OR TITLE:"BCL9 transcription coactivator" OR ABSTRACT:"BCL9 transcription coactivator" OR TITLE:"B-cell CLL/lymphoma 9 protein" OR ABSTRACT:"B-cell CLL/lymphoma 9 protein") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BCL9, not a curated reading list.